We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmacologic Control of Histamine Release from Human Basophils Induced by Platelet-Activating Factor.
- Authors
Columbo, Michele; Horowitz, Edward M.; McKenzie-White, Jane; Kagey-Sobotka, Anne; Lichtenstein, Lawrence M.
- Abstract
We studied the effect of several compounds that influence different cell activation steps on platelet-activating factor (PAF)-induced basophil histamine secretion. Isobutylmethylxanthine (1-100 μM), dimaprit (1-100 μM) and dibutyryl adenosine 3′,5′-cyclic phosphate (cAMP; 0.01-1 mM), that increase intracellular cAMP levels, concentration-dependently inhibited PAF-elicited histamine release. Rolipram (phosphodiesterase, PDE, isotype IV inhibitor; 0.1 nM-10 μM) potently inhibited histamine secretion activated by PAF, whereas SKF 95654 (PDE III inhibitor; 0.01-10 μM) was ineffective. The kinase inhibitor, staurosporine (0.1-100 μM), enhanced PAF-induced basophil histamine release, whereas the G-protein inhibitor, pertussis toxin (1 μg/ml), had an inhibitory effect. The specific lipoxygenase inhibitor, AA-861 (0.1-10 μM), inhibited PAF-activated histamine release, while the leukotriene A4 hydrolase inhibitor, bestatin (100 μM), had only a marginal effect. Finally, the Ca2+ channel entry blockers, verapamil (3-30 μM) and zinc (1.5-50 μM), inhibited PAF-induced histamine release. These results suggest that PAF is a unique secretagogue for human basophils unlike antigen, anti-IgE or univalent stimuli. Copyright © 1993 S. Karger AG, Basel
- Publication
International Archives of Allergy & Immunology, 1993, Vol 102, Issue 4, p383
- ISSN
1018-2438
- Publication type
Article
- DOI
10.1159/000236587